Coherus Oncology (CHRS) Net Margin Growth (3y) (2016 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) Net Margin Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 388.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -15,026.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -374.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -44.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 6,620.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -13,815.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 9,934.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,059.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.86 Mn |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | -7,119.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,119.00 |
| Mar 31, 2026 | -7,788.00 |
| Dec 31, 2025 | -16,548.00 |
| Sep 30, 2025 | -11,631.00 |
| Jun 30, 2025 | 298,728.00 |
| Mar 31, 2025 | -58,459.00 |
| Dec 31, 2024 | -59,324.00 |
| Sep 30, 2024 | -13,094.00 |
| Jun 30, 2024 | -9,138.00 |
| Mar 31, 2024 | 466,561.00 |
| Dec 31, 2023 | -9,579.00 |
| Sep 30, 2023 | -7,879.00 |
| Jun 30, 2023 | -11,907.00 |
| Mar 31, 2023 | -26,409.00 |
| Dec 31, 2022 | -16,148.00 |
| Sep 30, 2022 | -23,508.00 |
| Jun 30, 2022 | -11,162.00 |
| Mar 31, 2022 | -10,591.00 |
| Jun 30, 2020 | 426,191.00 |
| Mar 31, 2020 | 4.65 Mn |